I
Intas Pharmaceuticals Ltd5 To 14 P
Intas was founded in 1976. This company provides the manufacturing and research of pharmaceuticals. Their headquarters are located in Ahmedabad, Gujarat, India.
Country/Area ：India
Company Email ：support@intaspharma.com
Industry ：Health & MedicalLuggage, Bags & CasesManufacturing GeneralManufacturingMachinery
Company address ：Sola Bridge S.g. Hwy, Thaltej, Ahmedabad, Gujarat, 380054, India
Company website ：*****
Company phone ：+91 2717660100
Established ：1976
Company Revenue ：$2,701,472,000
Number of employees ：15987
SIC Code ：28283
NAICS Code ：32325
Main Products ：Adverse event reportingPlatform TechnologiesFactocel VIIICell & Gene Therapy CentreInternational operationsBiologics Business UnitTechnical SupportInvestor’s informationPlasma Fractionation CentreCentre of Cell & Gene Therapy>Click Here to know more about India’s Leading Plasma Fractionation CentreR & D
Company News
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
Oct 27, 2023
The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commercial milestone payments SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the develop
Oct 27, 2023
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara BiosimilarJul 17, 2023
SEOUL, South Korea--(BUSINESS WIRE)-- #DMB3115--European Medicine Agency confirmed acceptance of the Marketing Authorization Application for DMB-3115, a biosimilar of Stelara®.
Jul 17, 2023Accord BioPharma Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02Apr 5, 2023
The biosimilar for Herceptin seeks to treat several forms of HER2 cancer DURHAM, N.C., April 5, 2023 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today...
Apr 5, 2023Accord BioPharma Announces AccordConnects Inventory Management System for Hospitals and Healthcare PracticesJan 10, 2023
DURHAM, N.C., Jan. 10, 2023 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, today announced the launch of a mobile app and web-based inventory management capability,...
Jan 10, 2023Accord BioPharma Partners With StoryMDSep 21, 2022
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced... Read More The post Accord BioPharma Partners With StoryMD appeared first on citybiz.
Sep 21, 2022Business Info
CIN ：U24231GJ1985PLC007866
Registered State ：Gujarat
Registrar Of Companies ：RoC-Ahmedabad
Category ：Company limited by Shares
Sub Category ：Non-govt company
Company Class ：Public
Company Status ：Active
Registered Office Address ：Corporate House, Near Sola Bridge, S. G. Highway, Thaltej Ahmedabad Ahmedabad GJ IN 380054
Authorized Cap ：1739167520.00
Paidup Capital ：1147439720.00
Web Summary
Q1: What is the address of Intas Pharmaceuticals Ltd's corporate office?
A1: The address of Intas Pharmaceuticals Ltd's corporate office is Corporate House, Near Sola Bridge, S. G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, India.
Q2: What regulatory agencies have approved Intas Pharmaceuticals Ltd's facilities for operation?
A2: Intas Pharmaceuticals Ltd's facilities are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more.
Q3: What is the company's business model?
A3: Intas Pharmaceuticals Ltd is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing facility. This means that the company develops, manufactures, and markets its own pharmaceutical products.
Q4: What are some of the company's key strengths?
A4: Some of the company's key strengths include its segmentleading pipeline, strong inhouse development capabilities, and ability to compete with global players in innovation.
Q5: How has Intas Pharmaceuticals Ltd expanded its operations over the years?
A5: Over the years, Intas Pharmaceuticals Ltd has grown both organically and via acquisition, expanding its product portfolio and operations.
Q6: What is the company's focus on cell & gene therapy?
A6: Intas Pharmaceuticals Ltd has a Centre of Cell & Gene Therapy, which indicates that the company is actively involved in this area of research and development.
Q7: What types of products does Intas Pharmaceuticals Ltd manufacture?
A7: The text mentions various pharmaceutical products manufactured by Intas Pharmaceuticals Ltd, including Albucel, Amtas, Bevatas, Ceftas, Clavix, Cloba, Divaa, ELEFTHA, Epofit, Factocel, IX, Factocel VIII, Fibrogen I, Folisurge, Gabapin NT, Globucel, GlobucelSC, GlobucelVF, Hifenac P, IntaGlob, Levera, Lipicure, Looz, Mabtas, Prothrom, Rabium, ROMY, Terifrac, Thymotas, Valprol, Veltam, and Zenoxa.
Q8: What is the company's approach to innovation?
A8: The text mentions that Intas Pharmaceuticals Ltd aims to maximize its innovation capabilities to operate in global markets.
A1: The address of Intas Pharmaceuticals Ltd's corporate office is Corporate House, Near Sola Bridge, S. G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, India.
Q2: What regulatory agencies have approved Intas Pharmaceuticals Ltd's facilities for operation?
A2: Intas Pharmaceuticals Ltd's facilities are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more.
Q3: What is the company's business model?
A3: Intas Pharmaceuticals Ltd is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing facility. This means that the company develops, manufactures, and markets its own pharmaceutical products.
Q4: What are some of the company's key strengths?
A4: Some of the company's key strengths include its segmentleading pipeline, strong inhouse development capabilities, and ability to compete with global players in innovation.
Q5: How has Intas Pharmaceuticals Ltd expanded its operations over the years?
A5: Over the years, Intas Pharmaceuticals Ltd has grown both organically and via acquisition, expanding its product portfolio and operations.
Q6: What is the company's focus on cell & gene therapy?
A6: Intas Pharmaceuticals Ltd has a Centre of Cell & Gene Therapy, which indicates that the company is actively involved in this area of research and development.
Q7: What types of products does Intas Pharmaceuticals Ltd manufacture?
A7: The text mentions various pharmaceutical products manufactured by Intas Pharmaceuticals Ltd, including Albucel, Amtas, Bevatas, Ceftas, Clavix, Cloba, Divaa, ELEFTHA, Epofit, Factocel, IX, Factocel VIII, Fibrogen I, Folisurge, Gabapin NT, Globucel, GlobucelSC, GlobucelVF, Hifenac P, IntaGlob, Levera, Lipicure, Looz, Mabtas, Prothrom, Rabium, ROMY, Terifrac, Thymotas, Valprol, Veltam, and Zenoxa.
Q8: What is the company's approach to innovation?
A8: The text mentions that Intas Pharmaceuticals Ltd aims to maximize its innovation capabilities to operate in global markets.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
